Trial · NCT03134222
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 13 of 13
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12 | Lanraplenib 30 mg | -4.5 | Standard Error 1.91 | score on a scale | |
| Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12 | Filgotinib 200 mg | -8.7 | Standard Error 1.85 | score on a scale | |
| Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12 | Placebo | -5.5 | Standard Error 2.56 | score on a scale | |
| Percentage of Participants at Week 12 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline | Lanraplenib 30 mg | 47.4 | 95% Confidence Interval 24.4 to 71.1 | Percentage of participants | |
| Percentage of Participants at Week 12 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline | Filgotinib 200 mg | 64.7 | 95% Confidence Interval 38.3 to 85.8 | Percentage of participants | |
| Percentage of Participants at Week 12 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline | Placebo | 44.4 | 95% Confidence Interval 13.7 to 78.8 | Percentage of participants | |
| Percentage of Participants at Week 12 With No Worsening in CLASI Activity Score From Baseline | Lanraplenib 30 mg | 84.2 | 95% Confidence Interval 60.4 to 96.6 | Percentage of participants | |
| Percentage of Participants at Week 12 With No Worsening in CLASI Activity Score From Baseline | Filgotinib 200 mg | 94.1 | 95% Confidence Interval 71.3 to 99.9 | Percentage of participants | |
| Percentage of Participants at Week 12 With No Worsening in CLASI Activity Score From Baseline | Placebo | 88.9 | 95% Confidence Interval 51.8 to 99.7 | Percentage of participants | |
| Percentage of Participants at Week 24 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline | Lanraplenib 30 mg | 50.0 | 95% Confidence Interval 23.0 to 77.0 | Percentage of participants | |
| Percentage of Participants at Week 24 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline | Filgotinib 200 mg | 83.3 | 95% Confidence Interval 51.6 to 97.9 | Percentage of participants | |
| Percentage of Participants at Week 24 With No Worsening in CLASI Activity Score From Baseline | Lanraplenib 30 mg | 85.7 | 95% Confidence Interval 57.2 to 98.2 | Percentage of participants | |
| Percentage of Participants at Week 24 With No Worsening in CLASI Activity Score From Baseline | Filgotinib 200 mg | 100.0 | 95% Confidence Interval 73.5 to 100.0 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03134222/results